Consent Version Control, a Freezer Failure and a Delayed Ethics Report
A Phase III trial of seasonal malaria chemoprevention in children aged 3-59 months is running at a site in Kilifi with 640 participants enrolled. After protocol v4.0 and consent form v4.0 were approved - the new form adds a paragraph on the risk of febrile convulsions - the site continued using consent form v3.0 for 11 participants over three weeks. In the same period a freezer holding the investigational product failed overnight and reached -4 C; 60 doses were administered before the alarm log was reviewed. One participant had a seizure six days after dosing. The site recorded it as a serious adverse event and the sponsor notified the PPB within 24 hours, but the ethics committee was not informed until the annual report. The sponsor argues all of this is minor and wants enrolment to continue at full rate.
1. Classify the consent deviation and the product excursion. What must happen to the affected participants?
Read the worked answer
Consent deviation - major. The v4.0 form added information about a newly identified risk. Eleven participants, or their parents, consented without that information, so their consent was not fully informed. This is a serious breach affecting participants' rights and their ability to weigh the risk, and it is not cured by the fact that the omitted paragraph may not have changed anyone's decision - the right to be told is the point.
Actions: withdraw v3.0 from the site immediately and reconcile every consent form against the delegation log and the approval letter. Re-consent all 11 using v4.0, with the change explained in plain language by a member of staff not involved in the original consent, using an impartial witness where the parent cannot read. Document that participation is voluntary and that withdrawal will not affect care. Check whether the child who seized is in the 11; if so, the consent failure has a direct safety dimension.
Product excursion - potentially major. Reaching -4 C means the product froze. Freezing can irreversibly damage freeze-sensitive formulations - aggregation of an adjuvanted vaccine or precipitation of a drug - and damage is not visible. The 60 doses must be treated as an unapproved deviation: quarantine remaining stock, obtain a written stability assessment from the manufacturer, and do not release any vial for use without that documentation. The 60 exposed participants need follow-up for reduced efficacy, and the incident must be reported as a protocol deviation even though no harm has yet been observed.
2. Assess the serious adverse event reporting and decide whether enrolment should continue.
Read the worked answer
Reporting the seizure to the PPB within 24 hours was appropriate, but routing it only to the regulator and deferring the ethics committee to the annual report is not. An unexpected serious adverse reaction must go to the ethics committee within its stated timeline - commonly 7 days for fatal or life-threatening events and 15 days for other serious unexpected events, per the ICH E2A convention adopted in most national frameworks - and a seizure in a malaria chemoprevention trial is exactly the kind of event the committee needs contemporaneously. Annual reporting is for aggregate information, not for individual serious events.
On enrolment: this is a judgement about whether the site can still assure participant protection. Three independent failures in three weeks - consent version control, investigational product accountability, and safety reporting - point to a monitoring and quality system breakdown rather than isolated slips. A full study halt would be disproportionate if no further harm is likely and the site can correct quickly, but continuing at full rate is not defensible.
The proportionate decision is a partial hold on new enrolment at this site until three things are documented: all 11 participants re-consented, the investigational product assessed and dispositioned, and a corrective action plan accepted. Enrolment at other sites may continue if the failures are site-specific - which should be verified by a monitoring visit, not assumed.
3. What would you require from the sponsor and site, and by when?
Read the worked answer
Set deadlines in two tiers, because participant protection cannot wait for a full root cause analysis.
Within 7 days: a written deviation report covering both the consent failure and the product excursion; a list of the 11 participants with re-consent dates; the disposition decision for the affected product with the manufacturer's stability opinion; an immediate serious adverse event follow-up report to the ethics committee; and confirmation that no further v3.0 forms exist at the site or at any satellite clinic.
Within 30 days: root cause analysis of how an unapproved consent version entered the site file and stayed in use for three weeks - look at who controlled document versions, whether site staff were re-trained at v4.0 approval, and whether the delegation log was updated. A revised monitoring plan for the site, evidence of retraining, a full investigational product accountability reconciliation from the freezer alarm to the last dose, and a corrective action plan with named owners. The sponsor should also confirm whether the same document-control weakness exists at its other sites in the programme.
At the next monitoring visit: an effectiveness check - a source-document audit of 10 consecutively enrolled participants verifying consent version, product accountability records and adverse event reporting. If the check fails, escalate to suspension of the site and a referral for a GCP inspection.